CMV infection remains one of the major complication following solid organ transplantation with significant impact on patient and graft survival, however the strategies to diagnose and prevent this infection are quite heterogeneous in the different centers throughout Europe.

New drugs are on the horizon and might change the current practice of CMV preventive strategies, at least in the highest-risk group of recipients.

The purpose of this survey is to verify the strategies used to diagnose, prevent and treat CMV infection in European centers, according to country, type of organ, Donor/Recipient match and immunosuppressive regimens.

In addition, monitoring of CMV-specific T cell immunity is becoming a relevant tool to personalize preventive strategies and therefore some questions of the survey are directed to understand the current practice in the European transplant centers.

The survey will take about 20 minutes to be completed, and to thank every user who provides all answers, ESOT will provide a coupon code to access our e-learning platform, Transplant Live, for free for 1 year.

Once again, we would like to thank you for your contribution to this important survey. Its results may allow to design prospective multi-center European studies with the aim to improve the management of the most frequent infectious complication of solid organ transplant recipients.

Yours sincerely.

Prof. Paolo Grossi (Workgroup Coordinator)        
Dr Luciano Potena (ESOT President Elect)
Prof. Jose Maria Aguado
Prof. Fausto Baldanti
Prof. Bernhard Banas
Prof. Jens Gottlieb
Prof. Nassim Kamar
Dr John O’Grady
Prof. Faouzi Saliba

The European Society for Organ Transplantation thanks Merck for their generous support to this project.
2% of survey complete.